Maria Perez Morales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Perez Morales has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Padilla-Galo
Hospital Universitario Virgen de la Victoria, Malaga, Spain
3 shared publications - A. Levy-Naon
Pneumology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain
2 shared publications - B. Valencia Azcona
Pneumology Unit, 4th Floor, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain
2 shared publications - Begoña Tortajada Goitia
Hospital Costa del Sol, Marbella, España
2 shared publications - Casilda Olveira
Department of Medicine and Dermatology, Faculty of Medicine, University of Malaga, Málaga, 29016, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA)-BIONAND Platform, Málaga, 29590, Spain; Pneumology Department, Hospital Regional Universitario de Málaga, Málaga, 29010, Spain
2 shared publications - Francisco Rivas-Ruiz
IBIMA Plataforma BIONAND, Instituto de Investigación Biomédica de Málaga. Spain
2 shared publications
Latest Publications
- Open Access
- 27 May 2021
- Published by Springer Nature in Respiratory Research
- Vol. 22 (1) , 1-14
Real-life cost-effectiveness of benralizumab in patients with severe asthma
Background: Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma. Methods: This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-related quality of life) between a 1-year baseline treatment and 1-year benralizumab treatment. The health economic evaluation included direct costs and incremental cost-effectiveness ratios (ICERs). Results: After 1 year of treatment with benralizumab, patients with refractory eosinophilic asthma showed an improvement in all the effectiveness parameters analysed: improvement of asthma control and lung function, and decrease in the number of exacerbations, oral corticosteroid (both as corticosteroid courses and maintenance therapy), and inhaled corticosteroid use. The total annual cost per patient for the baseline and benralizumab treatment periods were €11,544 and €14,043, respectively, reflecting an increase in costs due to the price of the biological agent but a decrease in costs for the remaining parameters. The ICER was €602 per avoided exacerbation and €983.86 for every 3-point increase in the ACT score. Conclusions: All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.
- 27 May 2021
- Published by Springer Nature in Respiratory Research
- Vol. 22 (1) , 1-14
Open AccessReal-life cost-effectiveness of benralizumab in patients with severe asthma
Background: Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma. Methods: This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-related quality of life) between a 1-year baseline treatment and 1-year benralizumab treatment. The health economic evaluation included direct costs and incremental cost-effectiveness ratios (ICERs). Results: After 1 year of treatment with benralizumab, patients with refractory eosinophilic asthma showed an improvement in all the effectiveness parameters analysed: improvement of asthma control and lung function, and decrease in the number of exacerbations, oral corticosteroid (both as corticosteroid courses and maintenance therapy), and inhaled corticosteroid use. The total annual cost per patient for the baseline and benralizumab treatment periods were €11,544 and €14,043, respectively, reflecting an increase in costs due to the price of the biological agent but a decrease in costs for the remaining parameters. The ICER was €602 per avoided exacerbation and €983.86 for every 3-point increase in the ACT score. Conclusions: All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Concordance between pulmonologist performed rapid on-site evaluation (ROSE) and pathological diagnosis in EBUS-TBNA samples
Introduction: Sometimes it’s not easy have a pathologist to perform ROSE during an EBUS-TBNA procedure. Our objective was to analyze the concordance between ROSE performed by pulmonologists and the definitive pathological diagnosis. Methods: Retrospective analysis of EBUS-TBNA performed in our center, from february 2016 to september 2019, in which ROSE was performed by a pulmonologist through a fresh staining with panoptic rapid immersion technique. Results were reported as valid/suggestive, valid/non-suggestive and non-valid/non-suggestive, depending on lymphocytes and atypical cells presence. A comparison with the definitive pathological diagnosis is done, in all cases performed and those in which a malignancy diagnosis was obtained. Results: 453 EBUS-TBNA procedures analyzed in the study period, 198 met study criteria. Average age 64.08, 155 male sex. 437 punctures of hiliomediastinal lymph nodes (LN) were performed, average 3.66 punctures per LN. Punctured LN stations were 7 (n=140), 4R (n=104), 4L (n=58), 11L (n=34), 2R (n=31), 11R (n=29), 10R (n=19), 10L (n=8), 2L (n=8), 8 (n=4) and 3p (n=2). Valid/suggestive result was obtained in 104 patients (52.3%), valid/non-suggestive in 81 (40.9%) and non-valid /non-suggestive in 13 (6.6%). The overall concordance was considered as a moderate degree (kappa index 0.494). Concordance related to malignancy ROSE results (valid/suggestive) is considered as a high degree relation (kappa index 0.952), with sensitivity 98.9%, specificity 92.3% and NPV 92.3%. Conclusions: ROSE of EBUS-TBNA mediastinal LN cytological samples performed by pulmonologists show a high concordance in case of malignancy results.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Concordance between pulmonologist performed rapid on-site evaluation (ROSE) and pathological diagnosis in EBUS-TBNA samples
Introduction: Sometimes it’s not easy have a pathologist to perform ROSE during an EBUS-TBNA procedure. Our objective was to analyze the concordance between ROSE performed by pulmonologists and the definitive pathological diagnosis. Methods: Retrospective analysis of EBUS-TBNA performed in our center, from february 2016 to september 2019, in which ROSE was performed by a pulmonologist through a fresh staining with panoptic rapid immersion technique. Results were reported as valid/suggestive, valid/non-suggestive and non-valid/non-suggestive, depending on lymphocytes and atypical cells presence. A comparison with the definitive pathological diagnosis is done, in all cases performed and those in which a malignancy diagnosis was obtained. Results: 453 EBUS-TBNA procedures analyzed in the study period, 198 met study criteria. Average age 64.08, 155 male sex. 437 punctures of hiliomediastinal lymph nodes (LN) were performed, average 3.66 punctures per LN. Punctured LN stations were 7 (n=140), 4R (n=104), 4L (n=58), 11L (n=34), 2R (n=31), 11R (n=29), 10R (n=19), 10L (n=8), 2L (n=8), 8 (n=4) and 3p (n=2). Valid/suggestive result was obtained in 104 patients (52.3%), valid/non-suggestive in 81 (40.9%) and non-valid /non-suggestive in 13 (6.6%). The overall concordance was considered as a moderate degree (kappa index 0.494). Concordance related to malignancy ROSE results (valid/suggestive) is considered as a high degree relation (kappa index 0.952), with sensitivity 98.9%, specificity 92.3% and NPV 92.3%. Conclusions: ROSE of EBUS-TBNA mediastinal LN cytological samples performed by pulmonologists show a high concordance in case of malignancy results.
- Open Access
- 29 June 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-12
Real-life experience with benralizumab during 6 months
Background: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients.Methods: This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units.Results: A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7,p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7,p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75],p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0],p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1,p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12,p = 0.002). Side effects were mild and did not lead to treatment discontinuation.Conclusions: This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.
- 29 June 2020
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 20 (1) , 1-12
Open AccessReal-life experience with benralizumab during 6 months
Background: Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients.Methods: This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units.Results: A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7,p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7,p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75],p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0],p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1,p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12,p = 0.002). Side effects were mild and did not lead to treatment discontinuation.Conclusions: This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA2862
Characteristics of patients treated with nicotine replacement therapy (NRT) prescribed during hospitalization
Introduction: The aim of the study was to analyze the characteristics of patients and prescribers of treatment with NRT, after the implementation of a treatment program in our hospital for admitted smokers. Methods: A retrospective descriptive analysis of smokers treated during the period of hospitalization with NRT between 2013-2017 in our hospital, evaluating the diagnosis on admission, comorbidities, services involved, and effectiveness of the treatment at month, 6 months and 1 year after hospital discharge. Results: We obtained valid data in 88 patients, 53 (60.2%) males with mean age of 60.4 ± 12.06 years. The cumulative index of average tobacco was 52.25 ± 27.8 and the mean stay was 10.97 ± 9.28 days. The most frequent diagnosis on admission were COPD in 25% of cases, lung cancer in 10.2%, hemoptysis in 6.8%, pneumonia in 6.8%, stroke, digestive pathology and non-pulmonary cancer in 4.5% each one and finally ischemic heart disease in 3.4%. The comorbidities most frequently found were COPD (43.2%), arterial hypertension (35.2%), dyslipidemia (30.7%), depression (29.5%), diabetes (27.3%), alcoholism (25 %), anxiety (21.6%), drugs addiction (14.8%), lung cancer (13.6%), ischemic heart disease (12.5%) and stroke (10.2%). The majority of the patients were admitted in the Pneumology (54.5%) and Internal Medicine departments (23.9%). One month after discharge, 50% of them had quit smoking, at 6 months 40.9% and after one year 43.2%. Only 29.5% of treated patients were followed in a tobacco cessation unit after discharge. Conclusions: The follow-up after discharge in specialized units of tobacco cessation is very low, yet the efficacy of the treatment per year was high.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA2862
Characteristics of patients treated with nicotine replacement therapy (NRT) prescribed during hospitalization
Introduction: The aim of the study was to analyze the characteristics of patients and prescribers of treatment with NRT, after the implementation of a treatment program in our hospital for admitted smokers. Methods: A retrospective descriptive analysis of smokers treated during the period of hospitalization with NRT between 2013-2017 in our hospital, evaluating the diagnosis on admission, comorbidities, services involved, and effectiveness of the treatment at month, 6 months and 1 year after hospital discharge. Results: We obtained valid data in 88 patients, 53 (60.2%) males with mean age of 60.4 ± 12.06 years. The cumulative index of average tobacco was 52.25 ± 27.8 and the mean stay was 10.97 ± 9.28 days. The most frequent diagnosis on admission were COPD in 25% of cases, lung cancer in 10.2%, hemoptysis in 6.8%, pneumonia in 6.8%, stroke, digestive pathology and non-pulmonary cancer in 4.5% each one and finally ischemic heart disease in 3.4%. The comorbidities most frequently found were COPD (43.2%), arterial hypertension (35.2%), dyslipidemia (30.7%), depression (29.5%), diabetes (27.3%), alcoholism (25 %), anxiety (21.6%), drugs addiction (14.8%), lung cancer (13.6%), ischemic heart disease (12.5%) and stroke (10.2%). The majority of the patients were admitted in the Pneumology (54.5%) and Internal Medicine departments (23.9%). One month after discharge, 50% of them had quit smoking, at 6 months 40.9% and after one year 43.2%. Only 29.5% of treated patients were followed in a tobacco cessation unit after discharge. Conclusions: The follow-up after discharge in specialized units of tobacco cessation is very low, yet the efficacy of the treatment per year was high.